Summit Trail Advisors LLC Sells 4,663 Shares of Doximity, Inc. (NASDAQ:DOCS)

Summit Trail Advisors LLC cut its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,907 shares of the company's stock after selling 4,663 shares during the period. Summit Trail Advisors LLC's holdings in Doximity were worth $2,451,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DOCS. UMB Bank n.a. increased its holdings in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after buying an additional 235 shares during the period. Farther Finance Advisors LLC increased its stake in Doximity by 324.2% in the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company's stock valued at $34,000 after acquiring an additional 603 shares during the period. Morse Asset Management Inc acquired a new position in Doximity in the third quarter worth about $46,000. GAMMA Investing LLC lifted its stake in Doximity by 40.1% during the third quarter. GAMMA Investing LLC now owns 1,439 shares of the company's stock worth $63,000 after purchasing an additional 412 shares during the period. Finally, Covestor Ltd boosted its holdings in Doximity by 441.9% during the third quarter. Covestor Ltd now owns 1,680 shares of the company's stock valued at $73,000 after purchasing an additional 1,370 shares in the last quarter. Institutional investors own 87.19% of the company's stock.

Analyst Upgrades and Downgrades

DOCS has been the subject of a number of recent research reports. Bank of America increased their target price on Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. Wells Fargo & Company increased their price objective on Doximity from $43.00 to $55.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Stephens assumed coverage on shares of Doximity in a research note on Friday, December 20th. They issued an "equal weight" rating and a $55.00 target price on the stock. Needham & Company LLC upped their target price on shares of Doximity from $65.00 to $82.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Doximity from $30.00 to $48.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $64.22.

Doximity Stock Up 0.2 %

DOCS stock traded up $0.14 during midday trading on Friday, reaching $77.13. The stock had a trading volume of 2,886,369 shares, compared to its average volume of 2,391,105. The firm has a market cap of $14.40 billion, a price-to-earnings ratio of 77.13, a PEG ratio of 4.61 and a beta of 1.39. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The business has a fifty day simple moving average of $57.89 and a two-hundred day simple moving average of $47.37.

Insider Activity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 37.40% of the company's stock.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.